

**FACSIMILE TRANSMITTAL SHEET****FAX RECEIVED**

JUL 14 2003

**BRISTOL-MYERS SQUIBB COMPANY**

Patent Department

P. O. Box 5100

5 Research Parkway

Wallingford, CT 06492-7660

**GROUP 1600****TELECOPIER NO.: 203-677-6900****OFFICIAL**

<b>TO:</b>	Examiner Kamal A. Saeed PTO Art Unit 1626 fax: 703-308-4556
<b>FROM:</b>	Shah Makujina Bristol-Myers Squibb Company fax: 203-677-6900
<b>TOTAL NUMBER OF PAGES INCLUDING THIS ONE: 15</b>	
<i>If this fax is imperfectly received, please contact (203) 677-6877 immediately.</i>	
<b>DATE:</b>	July 11, 2003

**OFFICIAL  
CT 2666 NP****CERTIFICATE OF FACSIMILE TRANSMISSION**

I hereby certify that this paper (along with any paper referred to as being attached or enclosed) is being facsimile transmitted to 703-308-4556 at the Patent and Trademark Office on the date shown below.

Shah R. Makujina

Type or print name

Signature

7/11/03

Date

**IN THE UNITED STATES PATENT AND TRADEMARK OFFICE****Applicants:** Mattson, *et al.***Art Unit:** 1626**Serial No.:** 10/091,232**Examiner:** Kamal A. Saeed**Filed:** March 5, 2002**For:** CYCLOPROPYLINDOLE DERIVATIVES AS SELECTIVE SEROTONIN  
REUPTAKE INHIBITORS

MAIL STOP: Amendment  
Commissioner for Patents  
P.O. Box 1450  
Alexandria, VA 22313-1450

Dear Sir:

**AMENDMENT AND REPLY**

This Amendment and Reply is a timely response to Examiner's Office Action of May 19, 2003 with respect to the above referenced case and is timely submitted within the shortened statutory period of 3 months.

USSN 10/091,232

**OFFICIAL  
CT 2666 NP****Introductory Comments**

Of the claims as originally filed, claims 1-3, 6, 7, 9, 11, 13, 14, 16, 17, 19, 21, 22, 27-30 and 40-42 remain pending. All of said claims were objected to. None of said claims were rejected. Claims 4, 5, 8, 10, 12, 15, 18, 20, 23-26, 31-39 and 43-48 were previously canceled pursuant to Examiner's three-way restriction requirement of March 31, 2003, wherein Applicants elected Group I which was directed to "compounds and compositions of Formula I, depicted in claim 1". In the instant Amendment and Reply, Applicants respectfully request *inter alia* that claim 1, 40 and 41 be amended, claims 49-65 be added as described hereinbelow.